<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04089176</url>
  </required_header>
  <id_info>
    <org_study_id>T.Sopida</org_study_id>
    <nct_id>NCT04089176</nct_id>
  </id_info>
  <brief_title>Carbetocin Versus Oxytocin for Prevention of Postcesarean Hemorrhage in Pregnancy With High Risk for PPH</brief_title>
  <official_title>Carbetocin Versus Oxytocin for Prevention of Postcesarean Hemorrhage in Pregnant Women With High Risk Postpartum Hemorrhage: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rajavithi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rajavithi Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: study efficacy of carbtocin versus oxytocin for prevention postpartum hemorrhage
      in high risk pregnancy who undergo cesarean section
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized controlled clinical trial. Defined patient in two group. Primary outcome is
      evaluate additional drug use Secondary outcome is evaluated estimated blood loss, hemoglobin
      level
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Actual">May 31, 2019</completion_date>
  <primary_completion_date type="Actual">April 30, 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Additional drug use</measure>
    <time_frame>during intra-operation</time_frame>
    <description>Number of additional drug use after intervention drug</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimate blood loss</measure>
    <time_frame>During intra-opeartion and acute post operation period as 24 hours post operation</time_frame>
    <description>amount of blood loss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effect</measure>
    <time_frame>During intra-opeartion and acute post operation period as 24 hours post operation</time_frame>
    <description>type of side effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin level</measure>
    <time_frame>Pre-operation and 24 hours post operation</time_frame>
    <description>differentiation of hemoglobin</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Postpartum Hemorrhage</condition>
  <condition>Cesarean Section</condition>
  <condition>High Risk Pregnancy</condition>
  <arm_group>
    <arm_group_label>protocal A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carbetocin versus placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>protocal B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxytocin versus placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbetocin</intervention_name>
    <description>carbetocin 100 mcg + RLS solution 10 ml injected directly into the vein over 2 min</description>
    <arm_group_label>protocal A</arm_group_label>
    <arm_group_label>protocal B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxytocin</intervention_name>
    <description>oxytocin 20 IU diluted in 1000 ml of RLS solution administered intravenously at rate 120 ml/hr x 8 hr</description>
    <arm_group_label>protocal A</arm_group_label>
    <arm_group_label>protocal B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  previous history of postpartum hemorrhage

          -  polyhydramnios

          -  fetal macrosomia

          -  previous cesarean section

          -  grand multiparity

          -  intramural myoma

          -  chorioamnionitis

          -  prolonged premature rupture of membrane

          -  augmentation of labour

        Exclusion Criteria:

          -  pregnancy induce hypertension

          -  on anticoagulant

          -  placenta previa or placenta percreta
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rajavithi Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>April 28, 2019</study_first_submitted>
  <study_first_submitted_qc>September 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2019</study_first_posted>
  <last_update_submitted>September 11, 2019</last_update_submitted>
  <last_update_submitted_qc>September 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postpartum Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
    <mesh_term>Carbetocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

